Mandate

Vinge has advised Bilprovningen in connection with the sale of approx. 1/3 of its network of inspection stations

July 09, 2012

Vinge has advised Aktiebolaget Svensk Bilprovning in connection with the disposal of Besiktningskluster 1 AB to Opus Group AB (publ). Besiktningskluster 1 AB owns around 1/3 of Bilprovningen’s network of inspection stations and the disposal is part of the reregulation and competition exposure of the Swedish vehicle inspection market. Opus Group AB (publ) is listed on First North Premier (NASDAQ OMX) and develops, produces and sell products and services for, inter alia, vehicle inspections and repair workshops, and operates mandatory vehicle inspection programs in a number of countries. The purchase price amounts to approx. MSEK 375. The transaction is subject to, inter alia, accreditation approval.

The Vinge team was led by Carl Gustaf De Geer, Daniel Rosvall and Peter Sundgren and included lawyers from a number of practice areas such as M&A, Banking & Finance, EU &Antitrust, IT, Employment & Benefits, Real Estate, Intellectual Property and also entailed regulatory issues regarding the motor vehicle inspection legislation.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024